利凡斯的明
外观
| 臨床資料 | |
|---|---|
| 商品名 | Exelon, Prometax, others |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a602009 |
| 核准狀況 | |
| 懷孕分級 |
|
| 给药途径 | By mouth, transdermal patch |
| ATC碼 | |
| 法律規範狀態 | |
| 法律規範 |
|
| 藥物動力學數據 | |
| 生物利用度 | 60 to 72% |
| 血漿蛋白結合率 | 40% |
| 药物代谢 | Liver, via pseudocholinesterase |
| 生物半衰期 | 1.5 hours |
| 排泄途徑 | 97% in urine |
| 识别信息 | |
| |
| CAS号 | 123441-03-2 |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.120.679 |
| 化学信息 | |
| 化学式 | C14H22N2O2 |
| 摩尔质量 | 250.34 g·mol−1 |
| 3D模型(JSmol) | |
| |
| |
利凡斯的明(英語:Rivastigmine,商品名:忆思能,Exelon等)是一种含氮有机化合物,分子式C14H22N2O2,属于膽鹼酯酶抑制劑,用于治疗轻度至中度阿茲海默症[4]。
参考文献
[编辑]- ^ Prescription medicines: registration of new generic medicines and biosimilar medicines, 2017. Therapeutic Goods Administration (TGA). 21 June 2022 [30 March 2024]. (原始内容存档于2023-07-06).
- ^ Product monograph brand safety updates. Health Canada. 7 July 2016 [1 April 2024]. (原始内容存档于2024-03-29).
- ^ Anvisa. RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control]. Diário Oficial da União. 2023-03-31 (2023-04-04) [2023-08-16]. (原始内容存档于2023-08-03) (巴西葡萄牙语).
- ^ Khoury R, Rajamanickam J, Grossberg GT. An update on the safety of current therapies for Alzheimer's disease: focus on rivastigmine. Therapeutic Advances in Drug Safety (SAGE Publications). March 2018, 9 (3): 171–178. PMC 5810854
. PMID 29492246. doi:10.1177/2042098617750555.